Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences
In this week's "Psychedelic," recurring series focused on psychedelic stock news, looks back on a license agreement, enrollment completion and a patent filing. PHARMALA, JUPITER ENTER LICENSE AGREEMENT: PharmAla Biotech Holdings (MDXXF) announced Tuesday that it has entered into a definitive license agreement with Jupiter Neurosciences (JUNS) under which PharmAla has granted Jupiter an exclusive, perpetual, royalty-bearing license to develop, manufacture and commercialize ALA-002, PharmAla's lead drug candidate, in the United States. PharmAla retains all rights to ALA-002 outside the U.S. and will continue to advance the molecule internationally. Under the agreement, the total consideration payable to PharmAla is up to approximately $100M, consisting of a $3,333,333 upfront payment and up to $96,666,666 in contingent development, regulatory and commercialization milestone payments, plus royalties on all future U.S. net sales following the conclusion of milestone payments. The milestone payments and royalties are contingent on the achievement of specified development, regulatory and sales events, which may not be achieved. "This Agreement is a landmark transaction for PharmAla and.
In this week's "Psychedelic," recurring series focused on psychedelic stock news, looks back on a license agreement, enrollment completion and a patent filing.
PHARMALA, JUPITER ENTER LICENSE AGREEMENT: PharmAla Biotech Holdings (MDXXF) announced Tuesday that it has entered into a definitive license agreement with Jupiter Neurosciences (JUNS) under which PharmAla has granted Jupiter an exclusive, perpetual, royalty-bearing license to develop, manufacture and commercialize ALA-002, PharmAla's lead drug candidate, in the United States.
PharmAla retains all rights to ALA-002 outside the U.S. and will continue to advance the molecule internationally.
Under the agreement, the total consideration payable to PharmAla is up to approximately $100M, consisting of a $3,333,333 upfront payment and up to $96,666,666 in contingent development, regulatory and commercialization milestone payments, plus royalties on all future U.S. net sales following the conclusion of milestone payments.
The milestone payments and royalties are contingent on the achievement of specified development, regulatory and sales events, which may not be achieved. "This Agreement is a landmark transaction for PharmAla and.